Global researchers, including Tina Cascone of The University of Texas MD Anderson Cancer Center, have contributed to research regarding ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.
The project draws on contributions from translational medicine teams at AstraZeneca in Cambridge, Massachusetts, and Cambridge, UK, alongside clinical investigators at institutions including the University of Padova.
Global Research Collaboration
The collaborative effort brings together specialists from multiple international organizations and medical centers. Contributing teams and researchers include Lara McGrath from Translational Medicine, Oncology R&D at AstraZeneca in Cambridge, MA, and Gozde Kar from Translational Medicine, Early Data Science, Oncology R&D at AstraZeneca in Cambridge, UK.
Clinical and academic contributors span numerous institutions worldwide, including Laura Bonanno from the University of Padova and Istituto Oncologico Veneto IRCCS in Padova, Italy; Florian Guisier from Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Department of Pneumology and Inserm CIC-CRB 1404 in Rouen, France; Amelia Insa from the Medical Oncology Department at Hospital Clínico Universitario de Valencia in Valencia, Spain; and Moishe Liberman from the Division of Thoracic Surgery at the University of Montréal and CETOC – CHUM Endoscopic Tracheobronchial and Oesophageal Center, Centre Hospitalier de l’Université de Montréal in Montreal, Quebec, Canada.
Clinical and Development Network
Additional contributions to the oncology R&D initiative involve Olivier Bylicki from the Pneumology Department at Hôpital d’Instruction des Armées Sainte-Anne in Toulon, France; Lorenzo Livi from the Department of Radiation Oncology at the University of Florence in Florence, Italy; Thomas Egenod from the Department of Thoracic Oncology at Dupuytren University Hospital in Limoges, France; Romain Corre from the Department of Medical Oncology at CH de Cornouaille in Quimper, France; Dong-Wan Kim from the Department of Internal Medicine at Seoul National University College of Medicine and Seoul National Hospital in Seoul, South Korea; Maria Rosario Garcia Campelo from Hospital de A Coruña, Sergas, in A Coruña, Spain; Mariano Provencio Pulla from Puerta de Hierro University Hospital in Majadahonda, Spain; Byoung Yong Shim from the Department of Medical Oncology at The Catholic University of Korea, St. Vincent’s Hospital in Seoul, South Korea; Giulio Metro from Santa Maria della Misericordia Hospital, University of Perugia, in Perugia, Italy; and Jaafar Bennouna from the Department of Medical Oncology at Hôpital Foch in Suresnes, France.
🧬🫁 Can a blood test after just two cycles of neoadjuvant therapy predict relapse risk in resectable lung cancer?A new Nature study reports updated findings from NeoCOAST-2, a randomized phase II platform trial involving 202 patients with stage IIA–IIIB resectable NSCLC.The… pic.twitter.com/wE5kiOpL5C
Related reading
